LUCD: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Debt extinguishment loss - senior secured convertible note	-	0
Net loss attributable to lucid diagnostics inc	-41,744	-31,347
Depreciation and amortization expense	663	443
Stock-based compensation - lucid diagnostics inc. 2018 equity plan	3,227	2,092
Stock-based compensation - pavmed inc. 2014 equity plan	99	82
Change in fair value - senior secured convertible note	5,297	7,638
Equity issuance cost extinguishment	1,078	-
Amortization of common stock payment for vendor service agreement	234	147
Accounts receivable	505	328
Prepaid expenses and other current assets	1,225	942
Accounts payable	-490	-408
Accrued expenses and other current liabilities	-553	-407
Due to pavmed inc. - operating expenses, employee related costs, msa fee	12	16
Net cash flows used in operating activities	-33,907	-23,014
Purchase of equipment	146	118
Net cash flows used in investing activities	-146	-118
Proceeds issue of common stock - registered direct offering, net of fees	14,935	14,935
Proceeds issue of common stock - confidentially marketed public offering, net of fees	43,171	16,174
Proceeds issue of preferred stock	-	0
Proceeds issue of senior secured convertible notes	360	360
Proceeds issue of common stock at-the-market facility	274	274
Proceeds exercise of stock options	15	13
Proceeds issue common stock employee stock purchase plan	272	141
Net cash flows provided by financing activities	59,027	31,897
Net increase in cash	24,974	8,765
Cash and cash equivalents at beginning of period	22,358	-
Cash and cash equivalents at end of period	47,332	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

LUCD: the cashflow